Evidence map›Paper›PMID 37085479›Full record

ArticleNature communications2023

RNA binding protein SYNCRIP maintains proteostasis and self-renewal of hematopoietic stem and progenitor cells.

Florisela Herrejon Chavez, Hanzhi Luo, Paolo Cifani, Alli Pine, Eren L Chu, Suhasini Joshi, Ersilia Barin, Alexandra Schurer, Mandy Chan, Kathryn Chang and 12 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 4 countries.

Florisela Herrejon Chavez *Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-2238-0369
Hanzhi LuoMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Paolo CifaniMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alli PineComputational Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eren L ChuMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Suhasini JoshiChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ersilia BarinMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alexandra SchurerMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-8028-838X
Mandy ChanMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kathryn ChangMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Grace Y Q HanMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Aspen J PiersonMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael XiaoWeill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY, USA.
Xuejing YangMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lindsey M KuehmCell Microsystems, Inc., Durham, NC, USA.
Yuning HongDepartment of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, VIC, 3086, Australia.
Diu T T NguyenMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Gabriela ChiosisChemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-0486-6920
Alex KentsisMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Christina LeslieComputational Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-4571-5910
Ly P Vu *Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. lvu@bccrc.ca.ORCID http://orcid.org/0000-0002-1682-7702
Michael G KharasMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. kharasm@mskcc.org.ORCID http://orcid.org/0000-0002-1165-6991
Memorial Sloan Kettering Cancer Center · USCell Microsystems (United States) · USCornell University · USLa Trobe University · AU

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Single-Cell Biology Shared ResourceP30CA045508 · NCI · COLD SPRING HARBOR LABORATORY · PI John Edward Moses · 1987 to 2026
$118.9M
Mechanisms of epitranscriptomic regulation in cancerR01CA186702 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SAMIE R JAFFREY, Michael Kharas · 2014 to 2026
$8.0M
Uncovering the role for MSI2 network in hematopoietic stem cellsR01DK101989 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI Michael Kharas, Vijay Ganesh Sankaran · 2014 to 2026
$6.2M
ABERRANT SIGNALING IN ACUTE MYELOID LEUKEMIAR01CA204396 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KENTSIS, ALEX · 2016 to 2025
$5.2M
Characterizing the MSI2 network in leukemiaR01CA193842 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KHARAS, MICHAEL · 2015 to 2025
$4.1M
Identification of therapeutic targets for leukemia stem cells in AML-iPSC modelsR01CA225231 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KHARAS, MICHAEL, PAPAPETROU, EIRINI · 2018 to 2022
$3.2M
Molecular and genetic analysis of novel Slicer-dependent miRNA pathways in bloodR01HL135564 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI KHARAS, MICHAEL, LAI, ERIC C · 2017 to 2020
$2.9M
Understanding resistance mechanisms to protein arginine methyltransransferase Inhibitors in LymphomaR01CA274249 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Michael Kharas · 2023 to 2026
$2.8M
Multi-dimensional targeted mass spectrometry technology for pathway-scale functional proteomicsR21CA235285 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KENTSIS, ALEX · 2019 to 2021
$625k
Defining the molecular basis controlling hematopoietic stem cell symmetric and asymmetric divisions -supplementK99DK128602 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI LUO, HANZHI · 2021 to 2023
$235k
Translational Regulation by RNA Regulating Proteins in LeukemiaK99CA229993 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI VU, LY P · 2018 to 2018
$141k
NCI NIH HHS K99 CA229993NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA045508NCI NIH HHS R01 CA186702NCI NIH HHS R01 CA193842NCI NIH HHS R01 CA204396NCI NIH HHS R01 CA225231NCI NIH HHS R01 CA274249NCI NIH HHS R21 CA235285NHLBI NIH HHS R01 HL135564NIDDK NIH HHS K99 DK128602NIDDK NIH HHS R01 DK101989
6 · The paper itself

Abstract

Tissue homeostasis is maintained after stress by engaging and activating the hematopoietic stem and progenitor compartments in the blood. Hematopoietic stem cells (HSCs) are essential for long-term repopulation after secondary transplantation. Here, using a conditional knockout mouse model, we revealed that the RNA-binding protein SYNCRIP is required for maintenance of blood homeostasis especially after regenerative stress due to defects in HSCs and progenitors. Mechanistically, we find that SYNCRIP loss results in a failure to maintain proteome homeostasis that is essential for HSC maintenance. SYNCRIP depletion results in increased protein synthesis, a dysregulated epichaperome, an accumulation of misfolded proteins and induces endoplasmic reticulum stress. Additionally, we find that SYNCRIP is required for translation of CDC42 RHO-GTPase, and loss of SYNCRIP results in defects in polarity, asymmetric segregation, and dilution of unfolded proteins. Forced expression of CDC42 recovers polarity and in vitro replating activities of HSCs. Taken together, we uncovered a post-transcriptional regulatory program that safeguards HSC self-renewal capacity and blood homeostasis.

Indexed as

Hematopoietic Stem CellsHeterogeneous-Nuclear RibonucleoproteinsProteostasisAnimalsGene Expression RegulationMiceMice, KnockoutRNA-Binding ProteinsHeterogeneous-Nuclear RibonucleoproteinsRNA-Binding ProteinsSyncrip protein, mouse

Identifiers

PMID37085479
PMCPMC10121618
OpenAlexW4366742718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.